Valuation: Rekah Pharmaceutical Industry Ltd.

Market Cap 124M 12.4B 40.6M 35.15M 32.73M 30.08M 56.85M 3.87B 57.69M 386M 151M 1.93B 152M 149M 6.39B P/E 2024
24.5x
P/E 2025 -6.91x
Enterprise Value 252M 25.2B 82.54M 71.45M 66.52M 61.14M 116M 7.87B 117M 785M 308M 3.92B 310M 303M 12.99B EV / Sales 2024
0.87x
EV / Sales 2025 0.84x
Free-Float
17.21%
Yield 2024 *
-
Yield 2025 -
05-31 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-30 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
11-30 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25-08-31 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
25-05-29 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-03-30 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
24-11-25 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
24-08-28 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
24-05-27 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
24-03-26 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
23-11-28 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
23-08-31 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
23-05-29 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
1 day-1.99%
1 week-1.00%
1 month-0.73%
3 months-4.40%
6 months-7.57%
Current year-0.73%
1 week 1,062
Extreme 1062
1,144
1 month 1,006
Extreme 1006
1,144
Current year 1,006
Extreme 1006
1,348
1 year 1,006
Extreme 1006
1,348
3 years 1,006
Extreme 1006
1,788
5 years 1,006
Extreme 1006
2,610
10 years 1,006
Extreme 1006
4,076
Manager TitleAgeSince
Chief Executive Officer 82 1993-08-23
Director of Finance/CFO 46 2018-10-31
President 80 2010-06-27
Director TitleAgeSince
Chairman 82 2010-06-24
Director/Board Member 80 -
Chairman 80 2015-04-14
Change 5-day change 1-year change 3-year change Capi.($)
-1.99%-1.00%-8.66%-31.87% 40.43M
-1.08%+1.82%+22.52%+111.39% 100B
+1.30%+0.88%+47.46%+151.01% 53.87B
-0.68%+3.52%+2.80%+274.52% 23.74B
+0.60%+2.93%-12.64%-16.12% 8.37B
-1.29%+1.85%-33.43%-30.57% 7.56B
-1.53%+3.21%-7.75%-30.20% 6.92B
-1.14%-1.47%+23.29%+22.85% 6.16B
-1.83%-0.87%-0.52%+22.61% 5.29B
-.--%+2.79%-6.02%-3.62% 3.8B
Average -0.76%+1.08%+2.70%+47.00% 21.6B
Weighted average by Cap. -0.40%+1.64%+21.23%+118.01%

Financials

2024 2025
Net sales 322M 32.17B 105M 91.23M 84.93M 78.06M 148M 10.05B 150M 1B 393M 5B 396M 387M 16.59B 301M 30.1B 98.59M 85.35M 79.46M 73.03M 138M 9.4B 140M 938M 367M 4.68B 370M 362M 15.52B
Net income 6.21M 621M 2.03M 1.76M 1.64M 1.51M 2.85M 194M 2.89M 19.33M 7.57M 96.54M 7.63M 7.47M 320M -18.07M -1.81B -5.92M -5.13M -4.77M -4.39M -8.29M -565M -8.41M -56.3M -22.06M -281M -22.23M -21.74M -932M
Net Debt 127M 12.71B 41.63M 36.04M 33.55M 30.84M 58.28M 3.97B 59.14M 396M 155M 1.98B 156M 153M 6.55B 128M 12.8B 41.93M 36.3M 33.79M 31.06M 58.71M 4B 59.57M 399M 156M 1.99B 157M 154M 6.6B
Logo Rekah Pharmaceutical Industry Ltd.
Rekah Pharmaceutical Industry Ltd. (Rekah) is an Israel-based company which operates directly and through its subsidiaries. The Company operates two Good Manufacturing Practice (GMP) approved manufacturing sites, it has a marketing and distribution arm, a chain of pharmacies, and an export import unit. Rekah's plant covers approximately 5,000 square meters and was designed to take advantage of the most advanced and automated packaging techniques available. In April 1995, Rekah received the approval of the Ministry of Health for its new facility. The sterile department was designed to meet the standard of the United States Food and Drug Administration and was opened in February 1997. The Company distributes its products through Ophir & Shalpharm to institutional users such as Israel Health Funds, hospitals and government health facilities. Other subsidiaries include Vitamed Pharmaceutical Industry Ltd., CenterPharm, RITE, Talmor, BARBARA WOLF Ltd. and Madad.
Employees
390
Date Price Change Volume
26-07-31 ILA 1,086.00 -1.99% 3,403
26-07-30 ILA 1,108.00 +1.47% 9,576
26-07-29 ILA 1,092.00 +1.30% 95
26-07-28 ILA 1,078.00 +0.94% 1,207
26-07-27 ILA 1,068.00 -2.64% 1,114
  1. Stock Market
  2. Stocks
  3. REKA Stock